Skip to main content
. 2022 Apr 14;28(5):939–945. doi: 10.1038/s41591-022-01754-x

Extended Data Fig. 2. Patient flow.

Extended Data Fig. 2

153 patients were allocated to receive atezolizumab. One patient was not treated and was excluded from the primary analysis. The biomarker-evaluable population excluded patients with MSAF < 1% and assay quality control failures. bTMB, blood-based tumor mutational burden; MSAF, maximum somatic allele frequency; NSCLC, non-small cell lung cancer; QC, quality control. a Staging based on International Association for the Study of Lung Cancer Lung Cancer Staging Project 8th Edition of the TNM Classification for Lung Cancer28.